Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:IDYANASDAQ:INDVNASDAQ:MNMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$35.35+2.9%$31.65$23.42▼$62.58$1.99B0.73651,976 shs606,160 shsIDYAIDEAYA Biosciences$21.92+3.8%$20.16$13.45▼$44.42$1.85B0.031.03 million shs1.01 million shsINDVIndivior$15.40+5.0%$12.60$7.33▼$15.73N/A0.651.22 million shs1.44 million shsMNMDMind Medicine (MindMed)$7.08+6.0%$6.94$4.70▼$10.44$504.70M2.451.32 million shs1.25 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+3.34%+2.84%+6.11%+20.85%-20.77%IDYAIDEAYA Biosciences+0.48%-3.03%+5.34%+29.17%-41.20%INDVIndivior-0.54%+5.32%+15.25%+53.99%-6.92%MNMDMind Medicine (MindMed)+2.93%-6.44%-7.22%+11.89%-5.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.0627 of 5 stars3.41.00.04.21.80.81.9IDYAIDEAYA Biosciences3.6535 of 5 stars3.51.00.04.41.91.70.0INDVIndivior2.9527 of 5 stars2.63.00.00.03.21.71.9MNMDMind Medicine (MindMed)2.4934 of 5 stars3.63.00.00.01.90.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.71Moderate Buy$58.6065.77% UpsideIDYAIDEAYA Biosciences 2.93Moderate Buy$53.42143.69% UpsideINDVIndivior 3.25Buy$17.0010.39% UpsideMNMDMind Medicine (MindMed) 3.27Buy$25.50260.17% UpsideCurrent Analyst Ratings BreakdownLatest MNMD, AGIO, INDV, and IDYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025INDVIndiviorCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $22.006/26/2025IDYAIDEAYA BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$44.006/26/2025IDYAIDEAYA BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$44.005/22/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.005/13/2025MNMDMind Medicine (MindMed)Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/2/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M56.10N/AN/A$27.02 per share1.31IDYAIDEAYA Biosciences$7M274.25N/AN/A$12.25 per share1.79INDVIndivior$1.19BN/A$1.91 per share8.05($2.52) per shareN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/A$3.21 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.243.15N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)INDVIndivior$2M-$0.31N/A9.01N/A-4.02%-97.29%15.74%7/24/2025 (Estimated)MNMDMind Medicine (MindMed)-$108.68M-$1.29N/AN/AN/AN/A-40.33%-32.13%8/12/2025 (Estimated)Latest MNMD, AGIO, INDV, and IDYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/24/2025Q2 2025INDVIndivior$0.25N/AN/AN/AN/AN/A5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/A5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A18.5017.93IDYAIDEAYA BiosciencesN/A13.9213.92INDVIndiviorN/A0.880.72MNMDMind Medicine (MindMed)0.107.277.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AIDYAIDEAYA Biosciences98.29%INDVIndivior60.33%MNMDMind Medicine (MindMed)27.91%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.30%IDYAIDEAYA Biosciences2.50%INDVIndiviorN/AMNMDMind Medicine (MindMed)2.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million55.43 millionOptionableIDYAIDEAYA Biosciences8087.58 million85.39 millionOptionableINDVIndivior1,051N/AN/ANot OptionableMNMDMind Medicine (MindMed)4075.55 million73.70 millionOptionableMNMD, AGIO, INDV, and IDYA HeadlinesRecent News About These CompaniesMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Insider Sells $53,366.40 in StockJune 27, 2025 | insidertrades.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Insider Daniel Karlin Sells 7,848 SharesJune 26, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Insider Mark Sullivan Sells 11,491 SharesJune 26, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) CEO Robert Barrow Sells 26,491 SharesJune 26, 2025 | marketbeat.comMind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 5.4% - What's Next?June 25, 2025 | marketbeat.comMNMD Mind Medicine (MindMed) Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comMind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Up 6.3% - Here's WhyJune 18, 2025 | marketbeat.comMind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 4.8% - Here's WhyJune 11, 2025 | marketbeat.comEquities Analysts Offer Predictions for MNMD FY2026 EarningsJune 10, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Recommendation of "Buy" by BrokeragesJune 9, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Shares Sold by Two Sigma Investments LPJune 5, 2025 | marketbeat.comMillennium Management LLC Increases Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)June 5, 2025 | marketbeat.comWhy Mind Medicine Gave Investors a Powerful Buzz in MayJune 4, 2025 | msn.comBank of America Corp DE Reduces Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)June 4, 2025 | marketbeat.comWall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to TradeJune 2, 2025 | zacks.comMindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial OfficerMay 27, 2025 | finance.yahoo.comMindMed Announces New Employee Inducement GrantsMay 19, 2025 | businesswire.comDoes Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?May 13, 2025 | zacks.comWhy Mind Medicine (MindMed) Inc.’s (MNMD) Stock Is Up 5.37%May 12, 2025 | aaii.comAEarnings call transcript: MindMed Q1 2025 results show mixed signalsMay 10, 2025 | uk.investing.comMind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNMD, AGIO, INDV, and IDYA Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$35.35 +0.98 (+2.85%) Closing price 04:00 PM EasternExtended Trading$35.35 +0.00 (+0.00%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.IDEAYA Biosciences NASDAQ:IDYA$21.92 +0.80 (+3.79%) Closing price 04:00 PM EasternExtended Trading$21.92 +0.00 (+0.02%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Indivior NASDAQ:INDV$15.40 +0.74 (+5.05%) Closing price 04:00 PM EasternExtended Trading$15.19 -0.21 (-1.39%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Mind Medicine (MindMed) NASDAQ:MNMD$7.08 +0.40 (+5.99%) Closing price 04:00 PM EasternExtended Trading$7.04 -0.04 (-0.49%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
